Today's Rundown Alexion inks deal to acquire Achillion for $930M upfront Lilly's Armo buyout drug a bust in pancreatic cancer Roche dumps early pipeline efforts as sales jump [Sponsored] A New Starting Point for Patient Support: Technology-Driven Hub Services MedImmune's top cancer researcher jumps ship to small biotech Ipsen bags Blueprint drug to move deeper into ultra-rare disease Healx raises $56M to launch 40 rare disease R&D programs Novartis' Sandoz drops out of prescription app deal with Pear Therapeutics Featured Story | | | Wednesday, October 16, 2019 Alexion has struck a deal to buy Achillion for $930 million upfront. The takeover will give Alexion two clinical-phase medicines in development in complement alternative pathway-mediated rare diseases. |
|
|---|
|
Top Stories Wednesday, October 16, 2019 Last year, Eli Lilly spent $1.6 billion to get its hands on Armo Biosciences and its lead asset, pegilodecakin. Today, that drug flopped. Wednesday, October 16, 2019 Big Pharma giant Roche has quietly cut a series of early- to midstage experimental drugs as it continues the traditional quarterly clear-out. Monday, October 14, 2019 Flipping the script for specialty medications – improved patient access and time-to-therapy with a new tech-enabled platform from CoverMyMeds and RxCrossroads by McKesson. Wednesday, October 16, 2019 MedImmune’s vice president of research and head of oncology R&D Ronald Herbst, Ph.D., has followed a series of other AstraZeneca and its biologics arm staffers out the door. Wednesday, October 16, 2019 Ipsen has struck a deal with Blueprint Medicines to add another treatment for fibrodysplasia ossificans progressiva (FOP) to its rare disease pipeline. The backloaded, $535 million (€485 million) deal comes months after Ipsen paid $1 billion to buy Clementia Pharmaceuticals for an FOP therapy. Wednesday, October 16, 2019 Healx has raised $56 million (€51 million) to launch 40 rare disease programs while taking some of its existing assets into the clinic. The ambitious target is enabled by an AI drug discovery platform that Healx thinks gives it a scalability that has more in common with tech than biotech. Wednesday, October 16, 2019 Sandoz is pulling the plug on its commercialization partnership with Pear Therapeutics, ending its experiment with digital treatments for substance use disorders that first kicked off in April 2018. | | Experts in our field; with 20+ years of experience in Viral Vector and plasmid DNA (R&D, High Quality and GMP) manufacture for pre-clinical, clinical and commercial supply. Take a virtual tour of our facilities and find out more about our most recent expansion project. |
Resources Sponsored by: Outer Edge Technology Companies that don’t have a cloud strategy are at a competitive disadvantage. Why? The cloud has a measurable impact on business. Sponsored by: Medidata Simplified filing, improved oversight, audit readiness: is your eTMF system delivering best-in-class benefits? Sponsored by: Colorcon® Learn about how you better manage product authentication and battle drug counterfeiting with innovative solutions. Sponsored by: Cortellis, a Clarivate Analytics Solution Download this report for full details of Life sciences M&As in the second quarter of 2019 with notes and trends. Sponsored by: Elligo Health Research Find out how it leverages real-world data and novel IntElligo Research Stack™ technology to help researchers battle rising costs, cumbersome processes, and stagnant participation — bridging the gap between research and care. Sponsored by: InformedDNA Download this complimentary guide paper that explores key strategies for a successful genetics-informed clinical trial. Sponsored by: Life Image The time has finally come when medical imaging can be effectively utilized into the RWE process. Read the whitepaper on the best practices for incorporating Real World Imaging.™ Sponsored by: Patheon, by Thermo Fisher Scientific Is your API development on track? Sponsored by: BioAnalytix, Inc. Download the White Paper and learn how detailed characterization can guide successful development of gene therapy products. Sponsored by: ON24 Compare digital program performance and audience engagement among your life sciences peers. Sponsored by: Decision Resources Group Clinically Integrated Networks are vehicles for powerful IDNs to extend their influence into the physician sector and play a key role for IDNs trying to pave a path to becoming a self-contained healthcare ecosystem. Sponsored by: Reprints Desk, Inc. Slashing your R&D costs is easier than you think. Sponsored by: Roche and IQVIA A global landscape study of funding trends and innovations. Sponsored by: Blue Matter, strategic consultants in the life sciences White paper providing an overview of precision medicine in oncology, as well as a look ahead at future developments and keys to success for pharmaceutical and diagnostics companies. Sponsored by: Catalent Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study. Sponsored by: Catalent Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels. Sponsored by: Catalent Download the eBook to explore a proactive approach for clinical supply management. BioBasics: Biotech For The Non-Scientist Oct 22-23, 2019 | San Diego, CA 4th FierceBiotech Drug Development Forum October 28-29, 2019 | Boston, MA Drug Development Immersion November 7-8, 2019 | Boston, MA Advanced Therapies: Immunotherapies, Cell Therapies and Gene Therapies November 15, 2019 | Boston, MA Countdown to Drug Development Boot Camp® 2019 November 20-21, 2019 | Boston, MA | Register Now at www.drugstomarket.com/drugbootcamp and start Pre-Boot Camp Preparation | 